Literature DB >> 29866458

Congophilic Fibrillary Glomerulonephritis: A Case Series.

Mariam P Alexander1, Surendra Dasari2, Julie A Vrana3, Julie Riopel4, Anthony M Valeri5, Glen S Markowitz6, Aviv Hever7, Vanesa Bijol8, Christopher P Larsen9, Lynn D Cornell3, Mary E Fidler3, Samar M Said3, Sanjeev Sethi3, Loren Paola Herrera Hernandez3, Joseph P Grande3, Stephen B Erickson10, Fernando C Fervenza10, Nelson Leung10, Paul J Kurtin3, Samih H Nasr3.   

Abstract

RATIONALE &
OBJECTIVE: Congo Red positivity with birefringence under polarized light has traditionally permitted classification of organized glomerular deposits as from amyloid or nonamyloid diseases. The absence of congophilia has been used to differentiate fibrillary glomerulonephritis (GN) from amyloidosis. We describe a series of fibrillary GN cases in which the deposits are Congo Red-positive (congophilic fibrillary GN) and discuss the role of DNAJB9 in distinguishing congophilic fibrillary GN from amyloidosis. STUDY
DESIGN: Case series. SETTING & PARTICIPANTS: Analysis of the clinicopathologic characteristics of 18 cases of congophilic fibrillary GN. Mass spectrometry was performed and compared with 24 cases of Congo Red-negative fibrillary GN, 145 cases of amyloidosis, and 12 apparently healthy individuals. DNAJB9 immunohistochemistry was obtained for a subset of cases.
RESULTS: The proteomic signature of amyloid was not detected using mass spectrometry among cases of congophilic fibrillary GN. DNAJB9, a recently discovered proteomic marker for fibrillary GN, was detected using mass spectrometry in all cases of fibrillary GN regardless of congophilia and was absent in cases of amyloidosis and in healthy individuals. DNAJB9 immunohistochemistry confirmed the mass spectrometry findings. The congophilic fibrillary GN cases included 11 men and 7 women with a mean age at diagnosis of 65 years. Concomitant monoclonal gammopathy, hepatitis C virus infection, malignancy, or autoimmune disease was present in 35%, 22%, 17%, and 11% of patients, respectively. No patient had evidence of extrarenal amyloidosis. Patients presented with proteinuria (100%), nephrotic syndrome (47%), hematuria (78%), and chronic kidney disease (83%). After a mean follow-up of 23 months, 31% of patients progressed to end-stage kidney disease and the remaining 69% had persistently reduced kidney function. LIMITATIONS: Retrospective nature. Blinded pathology evaluations were not performed.
CONCLUSIONS: The congophilic properties of organized fibrillary deposits should not be solely relied on in differentiating fibrillary GN from renal amyloidosis. Mass spectrometry and DNAJB9 immunohistochemistry can be useful in making this distinction.
Copyright © 2018 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AL amyloidosis; Congo Red; DNAJB9; amyloid; biomarker; congophilic; fibrillary deposits; fibrillary glomerulonephritis; immunohistochemistry; kidney biopsy; laser microdissection; mass spectrometry; misdiagnosis; proteomics; renal pathology

Mesh:

Substances:

Year:  2018        PMID: 29866458     DOI: 10.1053/j.ajkd.2018.03.017

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  11 in total

1.  Clinicopathological characteristics and outcome of patients with fibrillary glomerulonephritis: DNAJB9 is a valuable histologic marker.

Authors:  Shaoshan Liang; Dacheng Chen; Dandan Liang; Feng Xu; Mingchao Zhang; Fan Yang; Xiaodong Zhu; Ping Li; Caihong Zeng
Journal:  J Nephrol       Date:  2020-06-18       Impact factor: 3.902

Review 2.  Pathophysiology and management of monoclonal gammopathy of renal significance.

Authors:  Ankur Jain; Richard Haynes; Jaimal Kothari; Akhil Khera; Maria Soares; Karthik Ramasamy
Journal:  Blood Adv       Date:  2019-08-13

3.  Fibrillary Glomerulonephritis: Clinicopathologic Features and Atypical Cases from a Multi-Institutional Cohort.

Authors:  Nicole K Andeen; Megan L Troxell; Maziar Riazy; Rupali S Avasare; Jessica Lapasia; J Ashley Jefferson; Shreeram Akilesh; Behzad Najafian; Roberto F Nicosia; Charles E Alpers; Kelly D Smith
Journal:  Clin J Am Soc Nephrol       Date:  2019-11-04       Impact factor: 8.237

Review 4.  Fibrillary Glomerulonephritis and DnaJ Homolog Subfamily B Member 9 (DNAJB9).

Authors:  Nattawat Klomjit; Mariam Priya Alexander; Ladan Zand
Journal:  Kidney360       Date:  2020-07-08

5.  Deciphering the autoimmune pathogenesis in fibrillary glomerulonephritis: The story is not yet complete.

Authors:  Muhammed Mubarak
Journal:  Indian J Nephrol       Date:  2021-11-13

Review 6.  Fibrillary Glomerulonephritis and Monoclonal Gammopathy: Potential Diagnostic Challenges.

Authors:  Yi Da; Giap Hean Goh; Titus Lau; Wee Joo Chng; Cinnie Yentia Soekojo
Journal:  Front Oncol       Date:  2022-05-25       Impact factor: 5.738

7.  IgM monoclonal gammopathy with heavy-and-light-chain amyloidosis resembling fibrillary glomerulonephritis determined by tandem mass spectrometry: a case report.

Authors:  Misa Adachi; Mineaki Kitamura; Kumiko Muta; Akihiro Maekawa; Tadashi Uramatsu; Masato Tadokoro; Satoshi Funakoshi; Satoshi Hisano; Naomi Kuwahara; Akira Shimizu; Hiroshi Mukae; Tomoya Nishino
Journal:  BMC Nephrol       Date:  2020-05-24       Impact factor: 2.388

8.  A 16-year Survey of Clinicopathological Findings, Electron Microscopy, and Classification of Renal Amyloidosis.

Authors:  Seyed Mohammad Owji; Hadi Raeisi Shahraki; Seyed Hossein Owji
Journal:  Iran J Med Sci       Date:  2021-01

9.  Characteristics of patients with coexisting DNAJB9-associated fibrillary glomerulonephritis and IgA nephropathy.

Authors:  Samar M Said; Alejandro Best Rocha; Anthony M Valeri; Mohamad Sandid; Anhisekh Sinha Ray; Mary E Fidler; Mariam Priya Alexander; Christopher P Larsen; Samih H Nasr
Journal:  Clin Kidney J       Date:  2020-12-05

10.  Successful treatment of a unique case of congophilic fibrillary glomerulonephritis: A case report.

Authors:  Pulkit Gandhi; Jie Tang
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.